Safety Efficacy Evidence Indication&Attributes Prescribing-information Previous Next Over A Decade of Improving Patient Outcomes Micardis PPARγ ACTIVATION 17/01/2022 | Author: Boehringer IngelheimPPARγ ACTIVATION IN A CELL-BASED TRANSIENT TRANSFECTION ASSAY. Document ID: PC-SA-101591 | Expiry Date: 28/04/2026 Efficacy Micardis 8% Reduction composite CV end point Micardis PPARγ ACTIVATION Micardis Vs. Other ARBS Micardis® has lowest renal excretion of clinically available arbs MICARDIS® (TELMISARTAN) SHOWS POWERFUL 24-H BP REDUCTION Micardis volume of distribution Micardis Longest Half life Related content Read more PDF Micardis Longest Half life PC-SA-101590 (April 2026 ) Download Opens in new tab Read more PDF Micardis volume of distribution PC-SA-101589 (April 2026 ) Download Opens in new tab Read more PDF MICARDIS® (TELMISARTAN) SHOWS POWERFUL 24-H BP REDUCTION PC-SA-101587 (April 2026 ) Download Opens in new tab Read more PDF MICARDIS® (TELMISARTAN) HAS LOWEST RENAL EXCRETION OF CLINICALLY AVAILABLE ARBs PC-SA-101592 (April 2026 ) Download Opens in new tab Read more PDF Micardis Vs. Other ARBS PC-SA-101588 (April 2026 ) Download Opens in new tab Read more PDF Micardis 8% Reduction composite CV end point PC-SA-101595 (May 2026 ) Download Opens in new tab Home Cardiovascular | Therapeutic Area Telmisartan Micardis PPARγ ACTIVATION
Read more PDF MICARDIS® (TELMISARTAN) SHOWS POWERFUL 24-H BP REDUCTION PC-SA-101587 (April 2026 ) Download Opens in new tab
Read more PDF MICARDIS® (TELMISARTAN) HAS LOWEST RENAL EXCRETION OF CLINICALLY AVAILABLE ARBs PC-SA-101592 (April 2026 ) Download Opens in new tab
Read more PDF Micardis 8% Reduction composite CV end point PC-SA-101595 (May 2026 ) Download Opens in new tab